Characteristics of pericortical enhancement
| Pericortical Enhancement | P Value | ||
|---|---|---|---|
| Yes (n = 21) | No (n = 53) | ||
| Demographics | |||
| Age (mean) (SD) (yr) | 73.5 (4.8) | 70.2 (6.4) | .02a |
| Female sex (No) (%) | 10 (48) | 22 (42) | .8 |
| Clinical subtype (No) (%) | .3 | ||
| Normal cognition | 5 (19) | 21 (81) | |
| MCI | 10 (30) | 23 (70) | |
| AD | 6 (40) | 9 (60) | |
| MRI characteristics | |||
| Fazekas scale score (median) (IQR) | 1.0 (1.0–3.0) | 1.0 (1.0–2.0) | .4 |
| Lacunar infarct present (No) (%) | 7 (33) | 8 (15) | .11 |
| Ischemic stroke present (No) (%) | 4 (19) | 3 (6) | .18 |
| Lacunar and/or ischemic stroke present (No) (%) | 9 (43) | 10 (19) | .04a |
| Microbleed present (No) (%) | 2 (10) | 7 (13) | 1.0 |
| Hemorrhagic stroke present (No) (%) | 1 (5) | 1 (2) | 1.0 |
| MTA score (median) (IQR) | 1.0 (0.5–2.25) | 0.5 (0–1.5) | .08 |
| Gadobutrol dosage (mean) (SD) (mL) | 7.3 (1.2) | 7.3 (1.1) | .98 |
| Cognitive performance | |||
| MMSE (median) (IQR)b | 28 (25–28) | 28 (26–29) | .97 |
| Genotype | |||
| ApoE4-positive (No) (%)c | 6 (30) | 25 (47) | .3 |